BOSTON, MA, March 13 /CNW/ - Cellzome Inc. announced today that it has
received the first milestone payment for its Gamma Secretase Modulator (GSM)
program in connection with the selection of a lead compound by Ortho-McNeil
Pharmaceutical, Inc. under its agreement with Cellzome. Ortho-McNeil entered
into a collaboration and license agreement with Cellzome in May 2005 and the
collaboration was extended for a further year in January 2007.
Tim Edwards, Cellzome's CEO, said: "I am delighted with the progress we
have made in our collaboration. This milestone payment is a reflection of the
continued productivity of Cellzome's drug discovery group in working with our
collaborator to advance toward preclinical development a potential oral
therapeutic for patients with Alzheimer's disease, and further demonstrates
the utility of our leading chemical proteomics technology."
About Cellzome Inc.
Cellzome is a privately owned drug discovery company applying its
world-class technology to the discovery of novel small molecule therapeutics.
Cellzome is commercializing its assets and technology by developing its own
pipeline of small molecule kinase inhibitors for inflammatory disease, and by
collaborating with leading pharmaceutical companies.
Cellzome's emerging pipeline includes a small molecule Histamine H4
receptor antagonist, initially for asthma and allergic rhinitis, which is
scheduled to begin clinical studies early 2008. In addition, Cellzome is
applying its distinctive Kinobeads(TM) technology to the discovery and
development of novel, selective, kinase inhibitors targeting key inflammatory
mediators in immune receptor signaling and chemotaxis, including ITK, ZAP70and
The Company also has a large non-exclusive research collaboration with
Novartis Institutes for Biomedical Research Inc. (NIBRI), using Cellzome's
leading proteomics capability to discover new drug targets and leads in a
variety of disease areas; this was recently extended to June 2008.
Cellzome is intent on developing both organically and through merger or
acquisition. Cellzome's holding company is domiciled in the USA and it employs
about 80 people in total at its facilities in Cambridge, UK and Heidelberg,
Germany. To learn more about Cellzome, please visit our website:
About Alzheimer's disease
Alzheimer's disease is an irreversible, progressive brain disease that
slowly destroys memory and thinking skills. It is the most common cause of
dementia in older people. About 20 million people are affected worldwide and
at the current rate the number is expected to double by 2025. In the United
States alone, more than 4.5 million people are currently afflicted with the
disorder, resulting in healthcare costs of close to $ 100 billion annually.
According to Cellzome estimates, this therapeutic market is currently valued
at about $4.7 billion in the major markets (US, UK, Germany, France, Italy,
Spain and Japan) and is expected to increase to $7.8 billion by the year 2010.
The first symptoms of Alzheimer's disease usually set in after the age of
60. With the degeneration of healthy brain tissue, intellectual and social
abilities are lost and patients eventually are left with little comprehension
Amyloid plaques are the pathological hallmark of Alzheimer's disease and
form as the disease develops in the brains of Alzheimer's patients. Genetic
studies in recent years have shown that the protein in these plaques, called
amyloid-beta or simply Abeta, is a central part of the mechanism that causes
the disease. Abeta peptide is generated from a large transmembrane precursor
protein, called APP, by two subsequent proteolytic cleavages that occur close
to, or within the membrane. The first cleavage is carried out by an aspartic
protease called gamma-secretase (BACE) and the second cleavage is carried out
by a multi-protein complex called gamma-secretase. Cellzome has mapped the
protein interaction network around this process and identified several target
For further information:
For further information: Cellzome Inc., Tim Edwards, Chief Executive
Officer, Tel: +49-(0)-6221-137-57-100, email@example.com; Media Contact:
Hogarth Partnership, John Olsen, Tel: +44-(0)-207-357-9477,